Enlicitide for hyperlipidemias

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Hypercholesterolemia

Why this status

  1. 14 Oct 2025: Trial registered, NCT07216482
  2. 11 Nov 2025: Trial started, NCT07216482

The trials

NCT07216482: A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

State
Completed
Phase
Phase 3
People
996 taking part
Started
11 Nov 2025
Primary completion
3 Aug 2026
Arms
Enlicitide, Enlicitide + Rosuvastatin
Results
None posted
  1. 14 Oct 2025: Trial registered
  2. 11 Nov 2025: Trial started
  3. 27 Oct 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.